Kiora Pharmaceuticals (KPRX) Short Interest Ratio & Short Volume

Short interest is the volume of Kiora Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of July 15th, investors have sold 18,000 shares of KPRX short. 0.67% of Kiora Pharmaceuticals' shares are currently sold short. Learn More on Kiora Pharmaceuticals' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.67% of Kiora Pharmaceuticals' floating shares are currently sold short.

Kiora Pharmaceuticals saw a decrease in short interest in the month of July. As of July 15th, there was short interest totaling 18,000 shares, a decrease of 55.4% from the previous total of 40,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Kiora Pharmaceuticals currently has issued a total of 2,920,000 shares. Some of Kiora Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Kiora Pharmaceuticals currently has a public float of 2,670,000 shares.

0.67% of Kiora Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Kiora Pharmaceuticals: DURECT Co. (4.18%), Aerovate Therapeutics, Inc. (4.38%), Atara Biotherapeutics, Inc. (13.40%), YS Biopharma Co., Ltd. (0.20%), BioXcel Therapeutics, Inc. (1.67%), ProMIS Neurosciences, Inc. (0.18%), IN8bio, Inc. (1.53%), Cue Biopharma, Inc. (7.65%), Natural Alternatives International, Inc. (0.08%), Lipocine Inc. (2.29%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.13 billion), Royal Caribbean Cruises Ltd. ($2.77 billion), Moderna, Inc. ($2.76 billion), Coinbase Global, Inc. ($2.36 billion), Rivian Automotive, Inc. ($2.22 billion), Paychex, Inc. ($2.02 billion), Tractor Supply ($1.81 billion), Enphase Energy, Inc. ($1.65 billion), Chesapeake Energy Co. ($1.62 billion), and Lululemon Athletica Inc. ($1.58 billion). View all of the most shorted stocks.

Short selling KPRX is an investing strategy that aims to generate trading profit from Kiora Pharmaceuticals as its price is falling. KPRX shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Kiora Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of KPRX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including KPRX, twice per month. The most recent reporting period available is July, 15 2024.